141 related articles for article (PubMed ID: 15800664)
1. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.
Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H
J Hum Hypertens; 2005 Jul; 19(7):569-76. PubMed ID: 15800664
[TBL] [Abstract][Full Text] [Related]
2. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
[TBL] [Abstract][Full Text] [Related]
3. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
Plosker GL; Keam SJ
Pharmacoeconomics; 2006; 24(12):1249-72. PubMed ID: 17129078
[TBL] [Abstract][Full Text] [Related]
4. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
McMurray JJ; Andersson FL; Stewart S; Svensson K; Solal AC; Dietz R; Vanhaecke J; van Veldhuisen DJ; Ostergren J; Granger CB; Yusuf S; Pfeffer MA; Swedberg K
Eur Heart J; 2006 Jun; 27(12):1447-58. PubMed ID: 16754631
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
6. The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses.
Trenkwalder P
J Hypertens Suppl; 2006 Mar; 24(1):S107-14. PubMed ID: 16601563
[TBL] [Abstract][Full Text] [Related]
7. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Nakamura T; Kanno Y; Takenaka T; Suzuki H;
Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
[TBL] [Abstract][Full Text] [Related]
8. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE).
Skoog I; Lithell H; Hansson L; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A;
Am J Hypertens; 2005 Aug; 18(8):1052-9. PubMed ID: 16109319
[TBL] [Abstract][Full Text] [Related]
9. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
[TBL] [Abstract][Full Text] [Related]
10. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review.
Zanchetti A; Elmfeldt D
Blood Press; 2006; 15(2):71-9. PubMed ID: 16754269
[TBL] [Abstract][Full Text] [Related]
11. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
Belsey JD
J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE).
Degl'Innocenti A; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A; Wiklund I
J Hum Hypertens; 2004 Apr; 18(4):239-45. PubMed ID: 15037872
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
[TBL] [Abstract][Full Text] [Related]
14. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
16. Cost implications of development of diabetes in the ALPINE study.
Lindholm LH; Kartman B; Carlberg B; Persson M; Svensson A; Samuelsson O
J Hypertens Suppl; 2006 Mar; 24(1):S65-72. PubMed ID: 16601576
[TBL] [Abstract][Full Text] [Related]
17. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y
Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543
[TBL] [Abstract][Full Text] [Related]
18. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
Suzuki H; Kanno Y;
Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
[TBL] [Abstract][Full Text] [Related]
19. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
20. The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients.
Trenkwalder P; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Papademetriou V; Skoog I; Zanchetti A;
Blood Press; 2005; 14(1):31-7. PubMed ID: 15823945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
